Biomerica

Biomerica EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Biomerica (BMRA) as of Oct 29, 2026 is -2.34. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.28 — a change of 82.03% (lower).

EV/FCF

-2.34

YoY

82.03%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Biomerica is 2026 -2.34 . EV/FCF (Enterprise Value to Free Cash Flow) of Biomerica was 2025 -1.28 . It decreases by 82.03% lower compared to the previous year.

The Biomerica EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-2.58 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.78 USD
Jan 1, 2022
-3.65 USD
Jan 1, 2023
0.31 USD
Jan 1, 2024
-0.64 USD
Jan 1, 2025
-1.28 USD
Jan 1, 2026
-2.34 USD
The Biomerica EV/FCF history
YEAREV/FCFYoY
-2.34+82.03%
-1.28+98.95%
-0.64-308.01%
0.31-108.48%
-3.65+367.52%
-0.78+6,019.45%
-0.01-99.50%
-2.58-41.08%
-4.38-37.00%
-6.95-57.98%
-16.54+22.07%
-13.55+187.15%
-4.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerica Stock analysis

What does Biomerica do? Biomerica, Inc. generates revenue through the development, manufacture, and marketing of medical diagnostic products for early detection and monitoring of chronic diseases. The company sells diagnostic test kits to clinical laboratories and point-of-care markets, analyzing blood, urine, or fecal specimens to measure specific bacteria, hormones, antibodies, antigens, or other substances. Its flagship product, InFoods IBS, offers diagnostic-guided therapy to identify patient-specific foods that may alleviate Irritable Bowel Syndrome symptoms when removed from the diet. The diagnostic test kits are used by clinical laboratories and point-of-care facilities to detect diseases through specimen analysis. InFoods IBS targets physicians seeking personalized dietary solutions for IBS patients, allowing them to identify foods that improve symptoms when eliminated. Biomerica focuses on chronic disease management with products designed for early detection and monitoring in both laboratory and point-of-care settings. Biomerica's revenue streams include sales of diagnostic test kits to clinical laboratories and point-of-care markets, as well as the InFoods IBS diagnostic-guided therapy product. The company serves healthcare providers and physicians who utilize these tools for patient diagnosis and treatment planning, particularly in managing chronic conditions like IBS through dietary adjustments. Biomerica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerica stock

EV/FCF (Enterprise Value to Free Cash Flow) of Biomerica is -2.34 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Biomerica changed from -1.28 to -2.34, representing a 82.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Biomerica since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Biomerica with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biomerica

All Key Metrics — Biomerica